GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JE, Holst JJ, Madsbad S, Torekov SS

The Journal of clinical endocrinology and metabolism4 Jun 2015Cited by 153 (Europe PMC)

PMID26043228DOI10.1210/jc.2015-1176PepBankPUB-26043228

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, total bone mineral content did not decrease significantly with liraglutide during weight maintenance, while it decreased in the control group.
In plain wordsIn weight-reduced obese women, bone mineral content did not drop significantly with liraglutide, but it dropped in the control group.
Peptide
Liraglutide
Outcome
No significant changeTotal bone mineral content (BMC) change
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322801
02HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, pelvic bone mineral content did not decrease significantly with liraglutide during weight maintenance, while it decreased in the control group.
In plain wordsIn weight-reduced obese women, pelvic bone mineral content did not drop significantly with liraglutide, but it dropped in the control group.
Peptide
Liraglutide
Outcome
No significant changePelvic bone mineral content (BMC) change
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322802
03HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, arm-leg bone mineral content did not decrease significantly with liraglutide during weight maintenance, while it decreased in the control group.
In plain wordsIn weight-reduced obese women, arm and leg bone mineral content did not drop significantly with liraglutide, but it dropped in the control group.
Peptide
Liraglutide
Outcome
No significant changeArm-leg bone mineral content (BMC) change
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322803
04HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, total and arm-leg bone mineral content loss was four times greater in the control group than in the liraglutide group, with an estimated difference of 27 g.
In plain wordsIn weight-reduced obese women, bone loss was four times greater without liraglutide than with it, although weight loss was kept in both groups.
Peptide
Liraglutide
Outcome
DecreaseTotal and arm-leg BMC loss versus control
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Measurements
estimated difference
27 g
control versus liraglutide
Source sentences
Summary
Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322804
05HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, the bone formation marker P1NP increased by 16% with liraglutide, versus a 2% decrease in the control group.
In plain wordsIn weight-reduced obese women, a marker of bone formation rose with liraglutide, while it fell slightly in the control group.
Peptide
Liraglutide
Outcome
IncreaseBone formation marker P1NP
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Measurements
P1NP increase
16%
liraglutide
P1NP decrease
2%
control
Source sentences
Summary
In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322805
06HumanRandomized controlled trialEfficacy outcome
In weight-reduced obese women, the bone resorption marker CTX-1 did not change during the weight loss maintenance phase.
In plain wordsIn weight-reduced obese women, a marker of bone breakdown did not change during weight maintenance.
Peptide
Liraglutide
Outcome
No significant changeBone resorption marker CTX-1
Study
n = 37
Comparator
Control (no liraglutide)
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1.2 mg/d · 52 weeksAs given in this study (human).
Source sentences
Summary
The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.
Summary · context
After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks.
Report a problemFND-2604322806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase not statedNCT07094568

Tirzepatide vs Liraglutide in Bone

National and Kapodistrian University of Athensn = 7223 May 2025 to est. 30 Dec 2026

Obesity (Disorder)

Trial page ClinicalTrials.govUpdated 21 Jan 2026

CompletedNot applicableNCT02094183

The Interaction Between Appetite Hormones

University of Copenhagenn = 58Sept 2011 to Apr 2014

Obesity

Trial page ClinicalTrials.govUpdated 8 Jul 2014

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.